Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

oleh: Shaun G. Goodman, Philippe Gabriel Steg, Yann Poulouin, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Genevieve Garon, Robert A. Harrington, J. Wouter Jukema, Garen Manvelian, Wanda Stipek, Michael Szarek, Harvey D. White, Gregory G. Schwartz